Arrowhead Pharmaceuticals Receives EC Approval for REDEMPLO to Reduce Triglycerides
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 22 2026
0mins
Arrowhead Pharmaceuticals announced that the European Commission has formally granted marketing authorization for REDEMPLO, a small interfering RNA medicine, as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronemia syndrome. REDEMPLO is the first and only siRNA medicine authorized by the EC for adults with FCS, diagnosed either by the presence of clinical criteria or genetic testing.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARWR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARWR
Wall Street analysts forecast ARWR stock price to fall
11 Analyst Rating
8 Buy
3 Hold
0 Sell
Moderate Buy
Current: 86.550
Low
35.00
Averages
82.00
High
110.00
Current: 86.550
Low
35.00
Averages
82.00
High
110.00
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. Its Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, neuromuscular and others. It has over 18 discovered drug candidates in clinical trials ranging from early stage (Phase I) to late stage (Phase III). The Company's pipeline products include plozasiran, zodasiran, olpasiran, ARO-RAGE, SRP-1002, GSK4532990, fazirsiran, daplusiran/tomligisiran, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, SRP-1001 (ARO-DUX4), SRP-1003 (ARO-DM1), SRP-1004 (ARO-ATXN2), and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Approves Tryngolza for Severe Hypertriglyceridemia Treatment
- FDA Approval: The U.S. FDA approved Tryngolza on Wednesday as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, based on CORE and CORE2 trials showing up to 72% triglyceride reduction at six months.
- Commercial Launch: Ionis plans to launch Tryngolza in the U.S. in July, administered as a once-monthly subcutaneous injection at doses of 50 mg or 80 mg, which is expected to significantly enhance treatment options for over three million Americans suffering from this condition.
- Positive Stock Reaction: Following the FDA approval, Ionis Pharmaceuticals (IONS) shares rose 4% in after-hours trading, with Goldman Sachs raising its price target to $75, although this implies about a 2% downside from the current stock price, indicating optimistic market sentiment towards the new drug.
- Analyst Ratings: According to Koyfin, 21 out of 24 analysts covering IONS rated it as 'Buy' or higher, with an average price target of $104.91, suggesting a potential upside of approximately 37% from Wednesday's closing price, reflecting strong confidence in Tryngolza's market potential.
See More
REDEMPLO Receives EU Approval for FCS Treatment
- New Treatment Option: REDEMPLO (plozasiran) becomes the first siRNA medicine authorized by the EU for adult patients with familial chylomicronemia syndrome (FCS), providing a treatment option without the need for genetic confirmation, addressing a critical unmet need for these rare disease patients.
- Clinical Data Support: The Phase 3 PALISADE study demonstrated that a 25 mg dose of REDEMPLO achieved an 80% reduction in triglyceride levels from baseline and an 83% reduction in the incidence of acute pancreatitis, showcasing its significant efficacy and long-term safety.
- Significant Market Potential: With FCS patients typically having triglyceride levels exceeding 10 mmol/L (880 mg/dL), the launch of REDEMPLO not only offers new hope for patients but also has the potential to drive Arrowhead's expansion in global markets, enhancing its leadership in RNA interference therapies.
- Accelerated Regulatory Progress: Arrowhead Pharmaceuticals plans to collaborate with relevant national authorities across the EU to swiftly bring REDEMPLO to market, reflecting its strong clinical data support and commitment to patient health, further solidifying its competitive edge in the RNAi therapeutic landscape.
See More
Arrowhead Pharmaceuticals Announces 2026 R&D Webinar Series
- 2026 Summer Webinar Series: Arrowhead Pharmaceuticals plans to host a series of R&D webinars in 2026, focusing on multiple clinical-stage RNA interference medicines utilizing its proprietary TRiM™ platform, aimed at enhancing market awareness in RNA therapeutics.
- Cardiometabolic Pipeline Focus: The first webinar is scheduled for June 29, 2026, concentrating on the cardiometabolic pipeline, featuring a keynote presentation by Dr. Steven Nissen from the Cleveland Clinic, showcasing Arrowhead's latest advancements in cardiovascular disease treatment.
- Diverse Agenda: Each webinar will last 60 to 90 minutes, covering Arrowhead's technology and R&D processes, clinical candidates, and discussions on relevant disease areas, designed to attract the attention of investors and healthcare professionals.
- Enhanced Market Engagement: Through these webinars, Arrowhead will provide live webcasts and replays, further enhancing interaction with investors and increasing the company's transparency and credibility in the biopharmaceutical industry.
See More
Arrowhead Pharmaceuticals to Participate in Upcoming Healthcare Conferences
- Conference Participation: Arrowhead Pharmaceuticals is scheduled to participate in the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 8:10 AM EDT, showcasing its advancements in RNA interference, which is expected to attract investor interest and enhance the company's visibility.
- Key Presentations: The company will also present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, at 9:00 AM EDT, highlighting its RNAi therapeutic solutions for intractable diseases, potentially fostering communication and collaboration with prospective partners.
- Platform Advantage: Arrowhead leverages its industry-leading TRiM™ platform to develop RNAi therapeutics that can precisely target various cell types, which is anticipated to enhance its competitiveness in clinical and commercial arenas while addressing significant unmet medical needs.
- Investor Relations: Presentation materials and webcast links will be accessible via the investor section of the company's website, aiming to strengthen communication with investors, enhance transparency, and attract more investor attention.
See More
Arrowhead Pharmaceuticals Presents New Clinical Data for Plozasiran at EAS Congress
- Clinical Data Support: Arrowhead Pharmaceuticals presented new clinical data for plozasiran at the 94th European Atherosclerosis Society Congress, indicating its use in patients with moderate-to-severe renal or moderate hepatic impairment without dose adjustment, highlighting the drug's importance in addressing patient needs.
- Safety Assessment: Despite modest increases in plozasiran exposure among patients with moderate-to-severe renal or moderate hepatic impairment, pharmacodynamic responses (APOC3 and triglyceride reduction) were similar to control cohorts, indicating good safety and tolerability of the drug in these populations.
- Pregnancy Impact: A case report suggests that preconception exposure to plozasiran may be associated with sustained lowering of triglyceride levels throughout pregnancy, providing new insights into the drug's application in special populations, although further data are needed to confirm its safety and efficacy.
- Future Research Directions: Arrowhead plans to conduct additional trials to further evaluate the safety of plozasiran in patients with liver or renal disease, underscoring the company's commitment to developing innovative therapies for unmet medical needs.
See More
Cardiovascular Disease Costs Set to Skyrocket, Urgent Need for AI Solutions
- Rising Cardiovascular Costs: The American Heart Association warns that U.S. heart disease costs are set to quadruple by 2050, with national healthcare spending nearing $5 trillion, compelling hospitals to rethink their diagnostic and treatment strategies for cardiac patients, thereby driving structural changes in the healthcare industry.
- Rapid Growth of AI Cardiology Market: The global AI cardiology market is projected to grow from $2.78 billion this year to over $14 billion by 2034, reflecting a strong demand for innovative technologies as health systems rush to deploy machine learning tools to address diagnostic backlogs.
- Showcasing VMS+™ 4.0 Technology: VentriPoint Diagnostics will showcase its AI-powered cardiac imaging platform at the AEPC conference in Italy, which converts standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRI without the need for expensive machines and long wait times.
- International Collaborations and Market Expansion: VentriPoint has established partnerships for regulatory approval of VMS+™ 4.0 in China and is promoting cardiac diagnostics in Costa Rica and Indigenous communities in Canada, demonstrating its potential for global market expansion and commercial momentum.
See More
FDA Approves Tryngolza for Severe Hypertriglyceridemia Treatment
- FDA Approval: The U.S. FDA approved Tryngolza on Wednesday as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, based on CORE and CORE2 trials showing up to 72% triglyceride reduction at six months.
- Commercial Launch: Ionis plans to launch Tryngolza in the U.S. in July, administered as a once-monthly subcutaneous injection at doses of 50 mg or 80 mg, which is expected to significantly enhance treatment options for over three million Americans suffering from this condition.
- Positive Stock Reaction: Following the FDA approval, Ionis Pharmaceuticals (IONS) shares rose 4% in after-hours trading, with Goldman Sachs raising its price target to $75, although this implies about a 2% downside from the current stock price, indicating optimistic market sentiment towards the new drug.
- Analyst Ratings: According to Koyfin, 21 out of 24 analysts covering IONS rated it as 'Buy' or higher, with an average price target of $104.91, suggesting a potential upside of approximately 37% from Wednesday's closing price, reflecting strong confidence in Tryngolza's market potential.
See More
REDEMPLO Receives EU Approval for FCS Treatment
- New Treatment Option: REDEMPLO (plozasiran) becomes the first siRNA medicine authorized by the EU for adult patients with familial chylomicronemia syndrome (FCS), providing a treatment option without the need for genetic confirmation, addressing a critical unmet need for these rare disease patients.
- Clinical Data Support: The Phase 3 PALISADE study demonstrated that a 25 mg dose of REDEMPLO achieved an 80% reduction in triglyceride levels from baseline and an 83% reduction in the incidence of acute pancreatitis, showcasing its significant efficacy and long-term safety.
- Significant Market Potential: With FCS patients typically having triglyceride levels exceeding 10 mmol/L (880 mg/dL), the launch of REDEMPLO not only offers new hope for patients but also has the potential to drive Arrowhead's expansion in global markets, enhancing its leadership in RNA interference therapies.
- Accelerated Regulatory Progress: Arrowhead Pharmaceuticals plans to collaborate with relevant national authorities across the EU to swiftly bring REDEMPLO to market, reflecting its strong clinical data support and commitment to patient health, further solidifying its competitive edge in the RNAi therapeutic landscape.
See More
Arrowhead Pharmaceuticals Announces 2026 R&D Webinar Series
- 2026 Summer Webinar Series: Arrowhead Pharmaceuticals plans to host a series of R&D webinars in 2026, focusing on multiple clinical-stage RNA interference medicines utilizing its proprietary TRiM™ platform, aimed at enhancing market awareness in RNA therapeutics.
- Cardiometabolic Pipeline Focus: The first webinar is scheduled for June 29, 2026, concentrating on the cardiometabolic pipeline, featuring a keynote presentation by Dr. Steven Nissen from the Cleveland Clinic, showcasing Arrowhead's latest advancements in cardiovascular disease treatment.
- Diverse Agenda: Each webinar will last 60 to 90 minutes, covering Arrowhead's technology and R&D processes, clinical candidates, and discussions on relevant disease areas, designed to attract the attention of investors and healthcare professionals.
- Enhanced Market Engagement: Through these webinars, Arrowhead will provide live webcasts and replays, further enhancing interaction with investors and increasing the company's transparency and credibility in the biopharmaceutical industry.
See More
Arrowhead Pharmaceuticals to Participate in Upcoming Healthcare Conferences
- Conference Participation: Arrowhead Pharmaceuticals is scheduled to participate in the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 8:10 AM EDT, showcasing its advancements in RNA interference, which is expected to attract investor interest and enhance the company's visibility.
- Key Presentations: The company will also present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, at 9:00 AM EDT, highlighting its RNAi therapeutic solutions for intractable diseases, potentially fostering communication and collaboration with prospective partners.
- Platform Advantage: Arrowhead leverages its industry-leading TRiM™ platform to develop RNAi therapeutics that can precisely target various cell types, which is anticipated to enhance its competitiveness in clinical and commercial arenas while addressing significant unmet medical needs.
- Investor Relations: Presentation materials and webcast links will be accessible via the investor section of the company's website, aiming to strengthen communication with investors, enhance transparency, and attract more investor attention.
See More
Arrowhead Pharmaceuticals Presents New Clinical Data for Plozasiran at EAS Congress
- Clinical Data Support: Arrowhead Pharmaceuticals presented new clinical data for plozasiran at the 94th European Atherosclerosis Society Congress, indicating its use in patients with moderate-to-severe renal or moderate hepatic impairment without dose adjustment, highlighting the drug's importance in addressing patient needs.
- Safety Assessment: Despite modest increases in plozasiran exposure among patients with moderate-to-severe renal or moderate hepatic impairment, pharmacodynamic responses (APOC3 and triglyceride reduction) were similar to control cohorts, indicating good safety and tolerability of the drug in these populations.
- Pregnancy Impact: A case report suggests that preconception exposure to plozasiran may be associated with sustained lowering of triglyceride levels throughout pregnancy, providing new insights into the drug's application in special populations, although further data are needed to confirm its safety and efficacy.
- Future Research Directions: Arrowhead plans to conduct additional trials to further evaluate the safety of plozasiran in patients with liver or renal disease, underscoring the company's commitment to developing innovative therapies for unmet medical needs.
See More
Cardiovascular Disease Costs Set to Skyrocket, Urgent Need for AI Solutions
- Rising Cardiovascular Costs: The American Heart Association warns that U.S. heart disease costs are set to quadruple by 2050, with national healthcare spending nearing $5 trillion, compelling hospitals to rethink their diagnostic and treatment strategies for cardiac patients, thereby driving structural changes in the healthcare industry.
- Rapid Growth of AI Cardiology Market: The global AI cardiology market is projected to grow from $2.78 billion this year to over $14 billion by 2034, reflecting a strong demand for innovative technologies as health systems rush to deploy machine learning tools to address diagnostic backlogs.
- Showcasing VMS+™ 4.0 Technology: VentriPoint Diagnostics will showcase its AI-powered cardiac imaging platform at the AEPC conference in Italy, which converts standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRI without the need for expensive machines and long wait times.
- International Collaborations and Market Expansion: VentriPoint has established partnerships for regulatory approval of VMS+™ 4.0 in China and is promoting cardiac diagnostics in Costa Rica and Indigenous communities in Canada, demonstrating its potential for global market expansion and commercial momentum.
See More
